Semaglutide vs Retatrutide
Semaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Retatrutide (triple GLP-1/GIP/glucagon agonist)
An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026 |
| Half-life | ~7 days | ~6 days |
| Molecular weight | 4,113.6 Da | ~4,731 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Agonizes GLP-1, GIP, and glucagon receptors. The added glucagon activity increases energy expenditure and hepatic fat oxidation, complementing the appetite and insulin effects of the incretin receptors. |
| Legal status (US) | FDA-approved, prescription only | Investigational, not approved for any indication |
Frequently asked questions
What is the difference between Semaglutide and Retatrutide?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. Retatrutide: An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.
Which has stronger research evidence, Semaglutide or Retatrutide?
Semaglutide is rated Strong and Retatrutide is rated Moderate for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Semaglutide and Retatrutide FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). Retatrutide: Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026.
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.